PDF(Pubmed)
Abstract：
UNASSIGNED: To compare the PRN anti-VEGF injection patterns of four retina specialists with respect to the visual and anatomic outcomes in the management of wet age-related macular degeneration (AMD).
UNASSIGNED: Medical records of patients who received bevacizumab, ranibizumab, and aflibercept anti-VEGF injections (years 2010-2020) by four retina specialists were reviewed for frequency, injection intervals, best corrected visual acuity (BCVA), and central macular thickness, center involved (CMT) for statistical analysis. Outcomes measured were change in logMAR BCVA and CMT from the first to last injection visit.
UNASSIGNED: Out of 137 AMD patients, 172 eyes were injected by four retina specialists in PRN fashion. Although all four specialists started the injection at similar baseline BCVA and CMT (p > 0.1), significant differences in mean injection number (9.0, p = 0.0001), injection intervals (5.06 weeks, p = 0.001), and total length of treatments (53.3 weeks, p = 0.0001) were observed. The mean change in logMAR BCVA between the first and last injection was -0.05, -0.22, 0.07, and 0.06 for the four specialists, respectively (p = 0.031), and the mean change in CMT was -53.3, -41.4, -72.7, and -21.9 µm (p = 0.41), respectively.
UNASSIGNED: Despite similar baseline criteria for injections by the retina specialists, different anti-VEGF injection regimens were practiced resulting in variations in BCVA and CMT outcomes. This suggests a need in establishing a universally adoptable injection regimen with possible integration of the confounding factors to reduce burden on both patients and retina specialists.
UNASSIGNED: Medical records of patients who received bevacizumab, ranibizumab, and aflibercept anti-VEGF injections (years 2010-2020) by four retina specialists were reviewed for frequency, injection intervals, best corrected visual acuity (BCVA), and central macular thickness, center involved (CMT) for statistical analysis. Outcomes measured were change in logMAR BCVA and CMT from the first to last injection visit.
UNASSIGNED: Out of 137 AMD patients, 172 eyes were injected by four retina specialists in PRN fashion. Although all four specialists started the injection at similar baseline BCVA and CMT (p > 0.1), significant differences in mean injection number (9.0, p = 0.0001), injection intervals (5.06 weeks, p = 0.001), and total length of treatments (53.3 weeks, p = 0.0001) were observed. The mean change in logMAR BCVA between the first and last injection was -0.05, -0.22, 0.07, and 0.06 for the four specialists, respectively (p = 0.031), and the mean change in CMT was -53.3, -41.4, -72.7, and -21.9 µm (p = 0.41), respectively.
UNASSIGNED: Despite similar baseline criteria for injections by the retina specialists, different anti-VEGF injection regimens were practiced resulting in variations in BCVA and CMT outcomes. This suggests a need in establishing a universally adoptable injection regimen with possible integration of the confounding factors to reduce burden on both patients and retina specialists.
摘要：
UNASSIGNED：比较四位视网膜专家在湿性年龄相关性黄斑变性（AMD）治疗中的视觉和解剖结果方面的PRN抗VEGF注射模式。
未经授权：接受贝伐单抗治疗的患者的医疗记录，雷珠单抗,和阿柏西普抗VEGF注射（2010-2020年）由四名视网膜专家进行了频率审查，注射间隔,最佳矫正视力（BCVA），和中央黄斑厚度，参与中心(CMT)进行统计分析。测量的结果是从第一次到最后一次注射访问的logMARBCVA和CMT的变化。
未经证实：在137名AMD患者中，由四位视网膜专家以PRN方式注射172只眼。尽管所有四位专家在相似的基线BCVA和CMT开始注射（p>0.1），平均注射次数存在显著差异(9.0，p=0.0001)，注射间隔（5.06周，p=0.001),和治疗的总长度（53.3周，观察到p=0.0001）。四位专家在第一次和最后一次注射之间logMARBCVA的平均变化为-0.05，-0.22，0.07和0.06，分别(p=0.031)，CMT的平均变化为-53.3、-41.4、-72.7和-21.9µm(p=0.41)，分别。
未经评估：尽管视网膜专家对注射的基线标准相似，采用不同的抗VEGF注射方案导致BCVA和CMT结局的差异.这表明需要建立一种普遍采用的注射方案，并可能整合混杂因素，以减轻患者和视网膜专家的负担。
未经授权：接受贝伐单抗治疗的患者的医疗记录，雷珠单抗,和阿柏西普抗VEGF注射（2010-2020年）由四名视网膜专家进行了频率审查，注射间隔,最佳矫正视力（BCVA），和中央黄斑厚度，参与中心(CMT)进行统计分析。测量的结果是从第一次到最后一次注射访问的logMARBCVA和CMT的变化。
未经证实：在137名AMD患者中，由四位视网膜专家以PRN方式注射172只眼。尽管所有四位专家在相似的基线BCVA和CMT开始注射（p>0.1），平均注射次数存在显著差异(9.0，p=0.0001)，注射间隔（5.06周，p=0.001),和治疗的总长度（53.3周，观察到p=0.0001）。四位专家在第一次和最后一次注射之间logMARBCVA的平均变化为-0.05，-0.22，0.07和0.06，分别(p=0.031)，CMT的平均变化为-53.3、-41.4、-72.7和-21.9µm(p=0.41)，分别。
未经评估：尽管视网膜专家对注射的基线标准相似，采用不同的抗VEGF注射方案导致BCVA和CMT结局的差异.这表明需要建立一种普遍采用的注射方案，并可能整合混杂因素，以减轻患者和视网膜专家的负担。
